Jinoos Yazdany

Jinoos Yazdany

Auto-generated profile, based on publicly available information

Jinoos Yazdany

University of California San Francisco San Francisco

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2020 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
LSLisa R. Sammaritano
Lisa R. Sammaritano
BBBonnie L. Bermas
Bonnie L. Bermas
ECEliza E. Chakravarty
Eliza E. Chakravarty
CCChristina D Chambers
Christina D Chambers
MCMegan E. B. Clowse
Megan E. B. Clowse
KDKristen E. D'ANci
Kristen E. D'ANci
Objective: To develop an evidence‐based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD).Methods: We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assessment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to determine final recommendations and grade their strength (conditional or strong). Good practice statements were agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary.Results: This American College of Rheumatology guideline provides 12 ungraded good practice statements and 131 graded recommendations for reproductive health care in RMD patients. These recommendations are intended to guide care for all patients with RMD, except where indicated as being specific for patients with systemic lupus erythematosus, those positive for antiphospholipid antibody, and/or those positive for anti‐Ro/SSA and/or anti‐La/SSB antibodies. Recommendations and good practice statements support several guiding principles: use of safe and effective contraception to prevent unplanned pregnancy, pre‐pregnancy counseling to encourage conception during periods of disease quiescence and while receiving pregnancy‐compatible medications, and ongoing physician‐patient discussion with obstetrics/gynecology collaboration for all reproductive health issues, given the overall low level of available evidence that relates specifically to RMD.Conclusion: This guideline provides evidence‐based recommendations developed and reviewed by panels of experts and RMD patients. Many recommendations are conditional, reflecting a lack of data or low‐level data. We intend that this guideline be used to inform a shared decision‐making process between patients and their physicians on issues related to reproductive health that incorporates patients’ values, preferences, and comorbidities.

8 April 2022 in Science
Verified
Journal Article
Closed access
RPRichard K. Perez
Richard K. Perez
MGM. Grace Gordon
M. Grace Gordon
MSMeena Subramaniam
Meena Subramaniam
MKMin Cheol Kim
Min Cheol Kim
GHGeorge C. Hartoularos
George C. Hartoularos
CYChun Jimmie Ye
Chun Jimmie Ye
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. Knowledge of circulating immune cell types and states associated with SLE remains incomplete. We profiled more than 1.2 million peripheral blood mononuclear cells (162 cases, 99 controls) with multiplexed single-cell RNA sequencing (mux-seq). Cases exhibited elevated expression of type 1 interferon–stimulated genes (ISGs) in monocytes, reduction of naïve CD4 + T cells that correlated with monocyte ISG expression, and expansion of repertoire-restricted cytotoxic GZMH + CD8 + T cells. Cell type–specific expression features predicted case-control status and stratified patients into two molecular subtypes. We integrated dense genotyping data to map cell type–specific cis–expression quantitative trait loci and to link SLE-associated variants to cell type–specific expression. These results demonstrate mux-seq as a systematic approach to characterize cellular composition, identify transcriptional signatures, and annotate genetic variants associated with SLE.

23 February 2020 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
LSLisa R. Sammaritano
Lisa R. Sammaritano
BBBonnie L. Bermas
Bonnie L. Bermas
ECEliza E. Chakravarty
Eliza E. Chakravarty
CCChristina Chambers
Christina Chambers
MCMegan E. B. Clowse
Megan E. B. Clowse
KDKristen E. D'ANci
Kristen E. D'ANci
Objective: To develop an evidence‐based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD).Methods: We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assessment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to determine final recommendations and grade their strength (conditional or strong). Good practice statements were agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary.Results: This American College of Rheumatology guideline provides 12 ungraded good practice statements and 131 graded recommendations for reproductive health care in RMD patients. These recommendations are intended to guide care for all patients with RMD, except where indicated as being specific for patients with systemic lupus erythematosus, those positive for antiphospholipid antibody, and/or those positive for anti‐Ro/SSA and/or anti‐La/SSB antibodies. Recommendations and good practice statements support several guiding principles: use of safe and effective contraception to prevent unplanned pregnancy, pre‐pregnancy counseling to encourage conception during periods of disease quiescence and while receiving pregnancy‐compatible medications, and ongoing physician‐patient discussion with obstetrics/gynecology collaboration for all reproductive health issues, given the overall low level of available evidence that relates specifically to RMD.Conclusion: This guideline provides evidence‐based recommendations developed and reviewed by panels of experts and RMD patients. Many recommendations are conditional, reflecting a lack of data or low‐level data. We intend that this guideline be used to inform a shared decision‐making process between patients and their physicians on issues related to reproductive health that incorporates patients’ values, preferences, and comorbidities.

25 February 2022 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
RGRebecca Grainger
Rebecca Grainger
AKAlfred Kim
Alfred Kim
RCRichard Conway
Richard Conway
JYJinoos Yazdany
Jinoos Yazdany
PRPhilip C. Robinson
Philip C. Robinson

26 February 2009 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
JYJinoos Yazdany
Jinoos Yazdany
PPPantelis Panopalis
Pantelis Panopalis
JGJoann Zell Gillis
Joann Zell Gillis
GSGabriela Schmajuk
Gabriela Schmajuk
CMCatherine H. MacLean
Catherine H. MacLean
SPSystemic Lupus Erythematosus Quality Indicators Project Expert Panels
Systemic Lupus Erythematosus Quality Indicators Project Expert Panels
Objective: To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE).Methods: We used a validated process that combined available scientific evidence and expert consensus to develop a QI set for SLE. We extracted 20 candidate indicators from a systematic literature review of clinical practice guidelines pertaining to SLE. An advisory panel revised and augmented these candidate indicators and, through 2 rounds of voting, arrived at 25 QIs. These QIs advanced to the next phase of the project, in which we employed a modification of the RAND/UCLA Appropriateness Method. A systematic review of the literature was performed for each QI, linking the proposed process of care to potential improved health outcomes. After reviewing this scientific evidence, a second interdisciplinary expert panel convened to discuss the evidence and provide final ratings on the validity and feasibility of each QI.Results: The final expert panel rated 20 QIs as both valid and feasible. Areas covered included diagnosis, general preventive strategies (e.g., vaccinations, sun avoidance counseling, and screening for cardiovascular disease), osteoporosis prevention and treatment, drug toxicity monitoring, renal disease, and reproductive health.Conclusion: We employed a rigorous multistep approach with systematic literature reviews and 2 expert panels to develop QIs for SLE. This new set of indicators provides an opportunity to assess health care quality in patients with SLE and represents an initial step toward the important goal of improving care in this patient population.

15 November 2010 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
JYJinoos Yazdany
Jinoos Yazdany
LTLaura Trupin
Laura Trupin
RKRachel Kaiser
Rachel Kaiser
GSGabriela Schmajuk
Gabriela Schmajuk
JGJoann Zell Gillis
Joann Zell Gillis
ESEleanor Bimla Schwarz
Eleanor Bimla Schwarz
Objective: Disease activity and medication use can complicate pregnancies in patients with systemic lupus erythematosus (SLE). We therefore examined contraceptive counseling and use among women in the University of California, San Francisco Lupus Outcomes Study.Methods: In 2008, we queried participants regarding their pregnancy intentions, contraceptive use, and receipt of contraceptive counseling. Premenopausal women age <45 years who were sexually active with men were considered at risk of pregnancy. We compared self‐reported rates of contraceptive counseling and use stratified by treatment with teratogenic medications and by history of thrombosis or antiphospholipid antibodies (aPL), using chi‐square tests. We used logistic regression models to examine predictors of contraceptive counseling and use.Results: Among 206 women, 86 were at risk for unplanned pregnancy. Most (59%) had not received contraceptive counseling in the last year, 22% reported inconsistent contraceptive use, and 53% depended solely on barrier methods. Intrauterine device contraceptives (IUDs) were used by 13%. Women using potentially teratogenic medications were no more likely to have received contraceptive counseling, to have used contraception consistently, or to have used more effective contraceptives. A history of thrombosis or aPL did not account for low rates of hormonal methods. Four women with a history of thrombosis or aPL were using estrogen‐containing contraceptives.Conclusion: Most women at risk for unplanned pregnancy reported no contraceptive counseling in the past year, despite common use of potentially teratogenic medications. Many relied upon contraceptive methods with high failure rates; few used IUDs. Some were inappropriately using estrogen‐containing contraceptives. These findings suggest the need to improve the provision of contraceptive services to women with SLE.